{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:15:56Z","timestamp":1763338556089,"version":"3.45.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiology Case Reports"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.radcr.2025.09.050","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:41:41Z","timestamp":1759794101000},"page":"122-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Symptomatic bone marrow involvement by metastatic occult HR+\/HER2- breast cancer treated with ribociclib and letrozole: A case report"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0896-7078","authenticated-orcid":false,"given":"Alfredo S.","family":"Golemba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0145-9525","authenticated-orcid":false,"given":"Adriana L.","family":"Jimenez Bola\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal E. Garc\u00eda","family":"Tolosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3480-1948","authenticated-orcid":false,"given":"Astor A.","family":"Aguirre Santamar\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.radcr.2025.09.050_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin."},{"issue":"5","key":"10.1016\/j.radcr.2025.09.050_bib0002","doi-asserted-by":"crossref","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radcr.2025.09.050_bib0003","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.breast.2018.03.002","article-title":"Global analysis of advanced\/metastatic breast cancer: decade report (2005-2015)","volume":"39","author":"Cardoso","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.radcr.2025.09.050_bib0004","doi-asserted-by":"crossref","unstructured":"Ofri A, Moore K. Occult breast cancer: where are we at? Breast. 2020;54:211\u2013215. doi: 10.1016\/j.breast.2020.10.012.","DOI":"10.1016\/j.breast.2020.10.012"},{"key":"10.1016\/j.radcr.2025.09.050_bib0005","article-title":"Best treatment options for occult breast cancer: a meta-analysis","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.radcr.2025.09.050_bib0006","doi-asserted-by":"crossref","first-page":"103756","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.radcr.2025.09.050_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinsp.2024.100362","article-title":"Visceral crisis in metastatic breast cancer: an old concept with new perspectives","volume":"79","author":"Andrade","year":"2024","journal-title":"Clinics (Sao Paulo)"},{"issue":"2","key":"10.1016\/j.radcr.2025.09.050_bib0008","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejso.2009.09.007","article-title":"Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review","volume":"36","author":"de Bresser","year":"2010","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1016\/j.radcr.2025.09.050_bib0009","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00330-002-1816-1","article-title":"Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions","volume":"13","author":"Walter","year":"2003","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.radcr.2025.09.050_bib0010","article-title":"Cutaneous metastatic breast cancer masked by hidradenitis suppurativa","volume":"13","author":"Cohen-Kurzrock","year":"2021","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.radcr.2025.09.050_bib0011","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ijwd.2018.08.002","article-title":"Scalp metastasis from occult primary breast carcinoma: a case report and review of the literature","volume":"4","author":"Alizadeh","year":"2018","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.radcr.2025.09.050_bib0012","first-page":"23","article-title":"Cutaneous metastasis of occult breast cancer: a case report","volume":"40","author":"da Costa","year":"2021","journal-title":"Pan Afr Med J"},{"issue":"10","key":"10.1016\/j.radcr.2025.09.050_bib0013","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.18790","article-title":"Regional lymph node involvement among patients with de novo metastatic breast cancer","volume":"3","author":"Bitencourt","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.radcr.2025.09.050_bib0014","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall survival with Palbociclib Plus Letrozole in advanced breast cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.radcr.2025.09.050_bib0015","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.radcr.2025.09.050_bib0016","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with Ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.radcr.2025.09.050_bib0017","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1186\/s13256-024-04922-4","article-title":"First-line endocrine therapy combined with CDK 4\/6 inhibitor in disseminated carcinomatosis of bone marrow (DCBM) luminal breast cancer: a case report","volume":"18","author":"Pangarsa","year":"2024","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.radcr.2025.09.050_bib0018","doi-asserted-by":"crossref","first-page":"1009352","DOI":"10.3389\/fonc.2022.1009352","article-title":"Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive\/HER2-negative metastatic breast cancer with visceral crisis: a case report","volume":"12","author":"Schettini","year":"2022","journal-title":"Front Oncol"},{"issue":"23","key":"10.1016\/j.radcr.2025.09.050_bib0019","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.24.00144","article-title":"Final results of RIGHT choice: Ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer","volume":"42","author":"Lu","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radcr.2025.09.050_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2261","volume":"35","author":"de la Haba Rodriguez","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Radiology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1930043325008957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1930043325008957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:12:31Z","timestamp":1763338351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1930043325008957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1930043325008957"],"URL":"https:\/\/doi.org\/10.1016\/j.radcr.2025.09.050","relation":{},"ISSN":["1930-0433"],"issn-type":[{"type":"print","value":"1930-0433"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Symptomatic bone marrow involvement by metastatic occult HR+\/HER2- breast cancer treated with ribociclib and letrozole: A case report","name":"articletitle","label":"Article Title"},{"value":"Radiology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radcr.2025.09.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of University of Washington.","name":"copyright","label":"Copyright"}]}}